Introduction
Chemotherapy is a form of cancer treatment whereby potent drugs are administered to destroy or inhibit cancer cells from proliferating. It is most commonly used to treat upper tract urothelial carcinoma (UTUC), a rare kidney and ureter lining cancer. Chemotherapy can be administered before surgery (neoadjuvant), after surgery (adjuvant), or for palliative treatment in severe cases. Urothelial carcinomas of the upper urinary tract are rare and have a less favorable prognosis at each stage than urothelial carcinomas of the bladder.
The POUT trial (perioperative chemotherapy vs. surveillance in upper tract urothelial carcinoma) was a clinical trial that tried to discover how beneficial platinum-based chemotherapy is for treating individuals with upper tract urothelial carcinoma (UTUC). This cancer occurs on the lining of the kidney or ureter. It was aimed to determine if administering chemotherapy shortly after surgery (perioperatively) would decrease the chances of cancer recurrence and enhance survival in comparison to waiting and monitoring.
What Is the Classification of the UTUC (Upper Tract Urothelial Carcinoma)?
-
Low-grade UTUC: It is less aggressive. Its ability to infiltrate deeper into the kidney or metastasize to other body parts is limited.
-
High-Grade UTUC: Advanced UTUC is more likely to infiltrate the kidney or other organs and spread to different body parts.
Cancer recurrence rates are higher for both low- and high-grade tumors. Individuals diagnosed with any type of UTUC should seek regular medical evaluations, as there is a high risk of cancer recurrence after therapy.
What Are the Symptoms and Early Warning Signs of UTUC?
Noticing the warning signs of upper tract urothelial carcinoma early is key to quick diagnosis and treatment.
The following are the most significant warning signs:
1. Blood in Urine
The most widespread symptom of UTOC is blood in hematuria or urine. It may be possible.
-
Visible (coarse) Hematuria: Urine seems pink, crimson, or brown.
-
Microscopic Hematuria: Blood is present, but only detected with laboratory tests.
While blood transfusions or kidney stones may cause blood in the urine, it is necessary to consult a doctor if it occurs.
2. Flank Pain:
-
Flank pain on one side of the lower back or one side of the stomach may indicate that the development of a tumor causes the ureter blockage.
Pain can be:
-
Stop in the initial stages.
-
Persistent and severe in advanced cases.
-
As a tumor grows, it can block urine flow and cause kidney infection (hydronephrosis). This infection can worsen the pain.
3. Painful or Burning Urination:
UTUC patients may have:
If you frequently urinate or experience discomfort (dysuria), it may be due to a urinary tract infection (UTI). These symptoms should improve with treatment, but if they persist thereafter, further evaluation is indicated.
4. Unexplained Weight Loss:
Sudden, unplanned weight loss without changes in food or exercise levels may indicate malignancy, especially UTUC.
This happens because:
-
The body's higher energy is needed to combat the sickness.
-
Cancer-related appetite loss.
If weight loss is accompanied by exhaustion or other UTUC symptoms, visit a doctor immediately.
5. Fatigue: Recurring fatigue or weakness could be a sign of body changes due to cancer. Fatigue in UTUC can be caused by:
-
Anemia.
-
Immune response to cancer.
-
Dehydration and renal impairment.
What Are the Chemotherapy Types That Are Used to Treat UTUC?
Chemotherapy options for UTUC can be administered in different ways depending on the stage and the aggressiveness of the cancer.
The primary types are:
-
Systemic chemotherapy is delivered through the blood to attack cancer cells.
-
Intravesical chemotherapy is applied directly into the bladder for local treatment of UTUC.
-
Neoadjuvant chemotherapy is employed preoperatively to decrease the size of tumors and improve surgical results.
-
Adjuvant chemotherapy is administered following surgery to eliminate any remaining cancer cells and prevent recurrence.
What are the Common Chemotherapy Drugs for UTUC?
Some of the most effective or most frequent chemotherapy agents for UTUC:
-
Cisplatin-based therapies are the most common form of chemotherapy for UTUC. It is usually administered along with Gemcitabine.
-
Carboplatin can be used in individuals who cannot tolerate Cisplatin.
-
Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) are combination therapies in advanced patients.
-
Gemcitabine and Cisplatin: An old-established therapeutic regimen for UTUC.
Side Effects of Chemotherapy for UTUC and How to Manage Them?
-
Loss of Appetite: Frequent, small, high-protein meals and nutritional supplements can be beneficial.
-
Low Blood Counts: This can lead to fatigue, bruising, or infection; regular monitoring and medications can aid recovery.
-
Increased Risk of Infection: Practice additional precautions such as handwashing, avoiding crowds, and fever watching.
-
Kidney Problems: Maintaining good hydration and regular kidney function tests is crucial, particularly with platinum-based chemotherapy.
-
Fatigue: Proper rest and diet can assist.
-
Hair loss is generally temporary and returns post-treatment.
-
Risk of Increased Infection - Special precautions must be taken due to a compromised immune system.
What Are the Phases of UTUC, and How Do They Influence the Treatment?
Treatment for UTUC depends on the phase of the disease:
Low-Grade, Non-Invasive UTUC:
Endoscopic Management (Ureteroscopy or Percutaneous Approach):
-
Applied to small, low-grade tumors.
-
Saves kidney function.
-
Needs routine follow-up and surveillance.
Topical Therapy (example: UGN-101/mitomycin gel):
-
Delivered directly into the upper tract through a catheter.
-
Beneficial for low-grade tumors in certain patients.
High-Grade or Invasive Localized UTUC:
Radical Nephroureterectomy (RNU):
-
Surgical extirpation of the kidney, ureter, and bladder cuff.
-
The gold standard for invasive or high-grade tumors.
Lymph Node Dissection:
-
Usually done in conjunction with RNU to evaluate the spread.
-
Perioperative chemotherapy.
-
Neoadjuvant (before surgery): Preferred because of better kidney function before removal.
-
Adjuvant (after surgery): Can be used if neoadjuvant chemo was not administered.
Locally Advanced or Metastatic UTUC:
-
Systemic Chemotherapy.
-
Platinum-based combinations such as Cisplatin + Gemcitabine.
-
Initial treatment of metastatic disease.
Immunotherapy:
-
Reserved for patients who cannot tolerate chemo or in the case of chemo failure.
-
Comprises immune checkpoint inhibitors (e.g., Pembrolizumab, Atezolizumab).
Targeted Therapy or Clinical Trials: It can be considered according to molecular characterization or failure of response to conventional therapy.
Conclusion
Upper tract urothelial carcinoma has not spread to other parts of the body and is typically diagnosed as a locally advanced disease. The prognosis for this form of disease is dismal since it usually recurs in different parts of the body. Upper and lower tract urothelial malignancies are treated differently, but the diseases are often analogous. Neoadjuvant chemotherapy is the standard of care in this context since it has been demonstrated to improve survival in well-executed phase III trials. There is not much evidence to support adjuvant treatment of bladder cancer, and it is challenging to deliver Cisplatin-based regimens to patients who might have reduced kidney function following a nephrectomy, making adjuvant therapy challenging for upper tract disease.
Key Takeaway/Note from Icliniq
The first identification of the upper course Eurotellial Carcinoma (UTC) is important for timely diagnosis, indicating warning signs such as hematuria, flank pain, and unexplained weight loss, as further evaluation is required. The difference between low- and high-quality UTOC is required to determine the most appropriate treatment method. In addition, being informed of new UTUC dishes, including intravenous therapy and progress in targeted medicines, can help adapt the patient's care and improve the results in the long term. For specialized medical guidance on UTOC diagnosis and treatment, contact experts at iCliniq.
